8-K
AVANOS MEDICAL, INC. (AVNS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: July 12, 2021
(Date of earliest event reported)
Commission file number 001-36440
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 46-4987888 | |||
|---|---|---|---|---|
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||
| 5405 Windward Parkway | ||||
| Suite 100 South | ||||
| Alpharetta, | Georgia | 30004 | ||
| (Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered |
|---|---|---|
| Common Stock - $0.01 Par Value | AVNS | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
Avanos Medical, Inc. (the “Company”) issued a press release on July 12, 2021, announcing that, effective that same day, Moji James was appointed as Senior Vice President & General Counsel of the Corporation. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release issued by Avanos Medical, Inc. on July 12, 2021 |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVANOS MEDICAL, INC. | |||
|---|---|---|---|
| Date: | July 12, 2021 | By: | /s/ S. Ross Mansbach |
| S. Ross Mansbach<br>Vice President, Deputy General Counsel and Corporate Secretary |
Document
Exhibit 99.1
| Investor Contact: Dave Crawford |
|---|
| Avanos Medical, Inc. |
| 470-448-5177 |
| Investor.Relations@Avanos.com |
| Media Contact: Katrine Kubis |
| Avanos Medical, Inc. |
| 470-448-5561 |
| CorporateCommunications@Avanos.com |
Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel
ALPHARETTA, Ga., July 12, 2021 / PRNewswire / -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Moji James has been appointed senior vice president & general counsel. In this role, James will oversee the Company’s legal, government relations and global security functions.
During her more than 25 years practicing law, James has supported the development and commercialization of innovative drugs, biologics and vaccines. She most recently served as executive vice president, chief legal and compliance officer of Tmunity Therapeutics, a biotherapeutics company, where she was responsible for legal affairs, compliance and risk management.
Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at Wyeth Pharmaceuticals (now part of Pfizer). Before joining Wyeth, she was a litigator at major law firms including Shearman & Sterling in New York, focusing her practice on complex commercial and securities issues.
“Moji’s extensive global and diversified legal experience, along with her knowledge of the healthcare sector and exceptional track record of managing complex business and legal strategies, makes her uniquely qualified for this role,” stated Joe Woody, chief executive officer. “In addition to her role as general counsel, I am excited to have Moji’s broad business experience and capabilities add to our overall strategy and vision of getting patients back to the things that matter.”
James holds a Bachelor of Laws degree from Warwick University, England, a Master of Laws degree from London University, and is also a barrister at law.
About Avanos Medical, Inc.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit Avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.